{"entity":{"id":"nct06468033","kind":"trial","name":"P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk","aka":[],"tldr":"A phase 3 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.","summary":"P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk is a phase 3 interventional study registered as NCT06468033 by PharmaEssentia, with 160 participants enrolled, started 2025-07-18 and due to reach its primary completion in 2027-11-18. Interventions recorded: Ropeginterferon alfa-2b, Placebo. Conditions listed: Primary Myelofibrosis, Myeloproliferative Neoplasm. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06468033","url":"https://clinicaltrials.gov/study/NCT06468033"}],"tags":["ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":["ropeginterferon-alfa-2b"],"companies":["pharmaessentia"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06468033","phase":"3","setting":"A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b (P1101) in Adult Patients With Pre-fibrotic/Early Primary Myelofibrosis (PMF) or Overt PMF at Low or Intermediate-1 Risk According to DIPSS Plus (HOPE-PMF): The Core Study and Its Extension Study","sponsor":"PharmaEssentia","enrolled":160,"outcomes":[]},"route":"/trials/nct06468033/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"drug":[{"id":"ropeginterferon-alfa-2b","kind":"drug","name":"Ropeginterferon alfa-2b","route":"/drugs/ropeginterferon-alfa-2b/"}],"company":[{"id":"pharmaessentia","kind":"company","name":"PharmaEssentia","route":"/companies/pharmaessentia/"}]}}